Activation of invasion by oncogenic reprogramming of cholesterol metabolism via increased NPC1 expression and macropinocytosis

Research output: Contribution to journalJournal articleResearchpeer-review

Documents

  • Fulltext

    Final published version, 4.8 MB, PDF document

Cancer cells are dependent on cholesterol, and they possess strictly controlled cholesterol homeostasis mechanisms. These allow them to smoothly switch between cholesterol synthesis and uptake to fulfill their needs and to adapt environmental changes. Here we describe a mechanism of how cancer cells employ oncogenic growth factor signaling to promote uptake and utilization of extracellular cholesterol via Myeloid Zinc Finger 1 (MZF1)-mediated Niemann Pick C1 (NPC1) expression and upregulated macropinocytosis. Expression of p95ErbB2, highly oncogenic, standard-treatment resistant form of ErbB2 mobilizes lysosomes and activates EGFR, invasion and macropinocytosis. This is connected to a metabolic shift from cholesterol synthesis to uptake due to macropinocytosis-enabled flow of extracellular cholesterol. NPC1 increase facilitates extracellular cholesterol uptake and is necessary for the invasion of ErbB2 expressing breast cancer spheroids and ovarian cancer organoids, indicating a regulatory role for NPC1 in the process. The ability to obtain cholesterol as a byproduct of increased macropinocytosis allows cancer cells to direct the resources needed for the energy-consuming cholesterol synthesis towards other activities such as invasion. These results demonstrate that macropinocytosis is not only an alternative energy source for cancer cells but also an efficient way to provide building material, such as cholesterol, for its macromolecules and membranes. [Figure not available: see fulltext.]

Original languageEnglish
JournalOncogene
Volume42
Pages (from-to)2495–2506
ISSN0950-9232
DOIs
Publication statusPublished - 2023

Bibliographical note

Funding Information:
This project has received funding from the Grosserer Alfred Nielsen og Hustrus Fond and from the European Union’s Horizon 2020 Research and Innovation programme under grant agreement No 965193 for DECIDER (TK), from the Danish Cancer Society Scientific Committee (KBVU) R273-A16.084 (AS) and R228-A13637 (ZW), from the Danish National Research Foundation DNRF125 (MJ) and Novo Nordisk Foundation, NNF19OC0054296 (MJ).

ID: 360026542